Cargando…

Diffuse large B-cell lymphoma: An institutional analysis

INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. We conducted a retrospective study to analyze the clinicopathological characteristics, cell of origin, response to therapy, and the outcome of patients with DLBCL. MATERIALS AND METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogia, Ajay, Das, Chandan K., Kumar, Lalit, Sharma, Atul, Tiwari, Akash, Sharma, M. C., Mallick, Soumya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma cell disorder
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069326/ https://www.ncbi.nlm.nih.gov/pubmed/30112341 http://dx.doi.org/10.4103/sajc.sajc_65_18

Ejemplares similares

Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol
por: Patekar, Mukesh, et al.
Publicado: (2018)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma
por: Madugula, Kiran K., et al.
Publicado: (2022)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Profile of non-Hodgkin lymphoma: An Indian perspective
por: Gogia, Ajay, et al.
Publicado: (2018)

Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile
por: Kwatra, Kanwardeep Singh, et al.
Publicado: (2017)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Follicular lymphoma: an Institutional Analysis
por: Gogia, Ajay, et al.
Publicado: (2017)

Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience
por: Rudresha, A. H., et al.
Publicado: (2017)

Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience
por: Das, Chandan Krushna, et al.
Publicado: (2016)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia: A single center experience
por: Gogia, Ajay, et al.
Publicado: (2014)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Large B-cell lymphomas
por: Vitolo, Umberto
Publicado: (2019)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way
por: Giannandrea, Domenica, et al.
Publicado: (2022)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
por: Giesen, Nicola, et al.
Publicado: (2022)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
por: Mangiacavalli, Silvia, et al.
Publicado: (2022)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders
por: Bruehl, Frido K., et al.
Publicado: (2023)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
por: Sigurbergsdóttir, Aðalbjörg Ýr, et al.
Publicado: (2023)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

A comparative study of bloodstream infections in acute myeloid leukemia according to different phases of treatment: Can we predict the organism?
por: Kalaskar, Preetam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c8fdd5gs0e5cmcrcibtopn4fu5